

Martin Stangel

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8380206/publications.pdf>

Version: 2024-02-01

270
papers

12,030
citations

25014

57
h-index

37183

96
g-index

288
all docs

288
docs citations

288
times ranked

13173
citing authors

#	ARTICLE	IF	CITATIONS
1	Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: A multicentre study of 175 patients. <i>Journal of Neuroinflammation</i> , 2012, 9, 14.	3.1	593
2	Transferrin receptor internalization sequence YXRF implicates a tight turn as the structural recognition motif for endocytosis. <i>Cell</i> , 1990, 63, 1061-1072.	13.5	525
3	Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study. <i>Lancet Neurology</i> , The, 2017, 16, 976-986.	4.9	472
4	Neuromyelitis optica: Evaluation of 871 attacks and 1,153 treatment courses. <i>Annals of Neurology</i> , 2016, 79, 206-216.	2.8	315
5	Astrocytes regulate myelin clearance through recruitment of microglia during cuprizone-induced demyelination. <i>Brain</i> , 2013, 136, 147-167.	3.7	298
6	Glial response during cuprizone-induced de- and remyelination in the CNS: lessons learned. <i>Frontiers in Cellular Neuroscience</i> , 2014, 8, 73.	1.8	293
7	Cortical Demyelination Is Prominent in the Murine Cuprizone Model and Is Strain-Dependent. <i>American Journal of Pathology</i> , 2008, 172, 1053-1061.	1.9	247
8	Regional differences between grey and white matter in cuprizone induced demyelination. <i>Brain Research</i> , 2009, 1283, 127-138.	1.1	199
9	Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (PATH): a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Neurology</i> , The, 2018, 17, 35-46.	4.9	193
10	The utility of cerebrospinal fluid analysis in patients with multiple sclerosis. <i>Nature Reviews Neurology</i> , 2013, 9, 267-276.	4.9	181
11	Apheresis therapies for NMOSD attacks. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2018, 5, e504.	3.1	173
12	De- and remyelination in the CNS white and grey matter induced by cuprizone: the old, the new, and the unexpected. <i>Histology and Histopathology</i> , 2011, 26, 1585-97.	0.5	169
13	Characterisation of microglia during de- and remyelination: Can they create a repair promoting environment?. <i>Neurobiology of Disease</i> , 2012, 45, 519-528.	2.1	161
14	Towards the implementation of "no evidence of disease activity"™ in multiple sclerosis treatment: the multiple sclerosis decision model. <i>Therapeutic Advances in Neurological Disorders</i> , 2015, 8, 3-13.	1.5	145
15	Longitudinal extensive transverse myelitis—it's not all neuromyelitis optica. <i>Nature Reviews Neurology</i> , 2011, 7, 688-698.	4.9	141
16	Fumaric acid and its esters: An emerging treatment for multiple sclerosis with antioxidative mechanism of action. <i>Clinical Immunology</i> , 2012, 142, 44-48.	1.4	140
17	Sequential myelin protein expression during remyelination reveals fast and efficient repair after central nervous system demyelination. <i>Neuropathology and Applied Neurobiology</i> , 2008, 34, 105-114.	1.8	134
18	Novel multiple sclerosis susceptibility loci implicated in epigenetic regulation. <i>Science Advances</i> , 2016, 2, e1501678.	4.7	133

#	ARTICLE	IF	CITATIONS
19	Immunotherapies in neuromyelitis optica spectrum disorder: efficacy and predictors of response. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2017, 88, 639-647.	0.9	123
20	Cuprizone [Bis(Cyclohexylidenehydrazide)] is Selectively Toxic for Mature Oligodendrocytes. <i>Neurotoxicity Research</i> , 2013, 24, 244-250.	1.3	122
21	Remyelinating strategies for the treatment of multiple sclerosis. <i>Progress in Neurobiology</i> , 2002, 68, 361-376.	2.8	121
22	Drug Insight: the use of intravenous immunoglobulin in neurology—therapeutic considerations and practical issues. <i>Nature Clinical Practice Neurology</i> , 2007, 3, 36-44.	2.7	121
23	Demyelination of the hippocampus is prominent in the cuprizone model. <i>Neuroscience Letters</i> , 2009, 451, 83-88.	1.0	118
24	CXCL10 Triggers Early Microglial Activation in the Cuprizone Model. <i>Journal of Immunology</i> , 2015, 194, 3400-3413.	0.4	115
25	Low-Frequency and Rare-Coding Variation Contributes to Multiple Sclerosis Risk. <i>Cell</i> , 2018, 175, 1679-1687.e7.	13.5	115
26	Ocrelizumab Depletes CD20+ T Cells in Multiple Sclerosis Patients. <i>Cells</i> , 2019, 8, 12.	1.8	109
27	Chronic toxic demyelination in the central nervous system leads to axonal damage despite remyelination. <i>Neuroscience Letters</i> , 2009, 453, 120-125.	1.0	108
28	H2O2 and Nitric Oxide-mediated Oxidative Stress Induce Apoptosis in Rat Skeletal Muscle Myoblasts. <i>Journal of Neuropathology and Experimental Neurology</i> , 1996, 55, 36-43.	0.9	98
29	Intravenous immunoglobulin treatment of neurological autoimmune diseases. <i>Journal of the Neurological Sciences</i> , 1998, 153, 203-214.	0.3	94
30	Epileptic seizures and hippocampal damage after cuprizone-induced demyelination in C57BL/6 mice. <i>Experimental Neurology</i> , 2008, 210, 308-321.	2.0	94
31	CCL5 induces a pro-inflammatory profile in microglia in vitro. <i>Cellular Immunology</i> , 2011, 270, 164-171.	1.4	92
32	Achievements and obstacles of remyelinating therapies in multiple sclerosis. <i>Nature Reviews Neurology</i> , 2017, 13, 742-754.	4.9	89
33	Autoantibodies against aquaporin-4 in patients with neuropsychiatric systemic lupus erythematosus and primary Sjögren's syndrome. <i>Arthritis and Rheumatism</i> , 2010, 62, 1198-1200.	6.7	88
34	Effectors of Th1 and Th17 cells act on astrocytes and augment their neuroinflammatory properties. <i>Journal of Neuroinflammation</i> , 2017, 14, 204.	3.1	88
35	Side effects of intravenous immunoglobulins in neurological autoimmune disorders. <i>Journal of Neurology</i> , 2003, 250, 818-821.	1.8	86
36	Cerebellar Cortical Demyelination in the Murine Cuprizone Model. <i>Brain Pathology</i> , 2010, 20, 301-312.	2.1	86

#	ARTICLE	IF	CITATIONS
37	Expression of the chemokine receptors CXCR1 and CXCR2 in rat oligodendroglial cells. <i>Developmental Brain Research</i> , 2001, 128, 77-81.	2.1	84
38	Type I Interferon Receptor Signaling of Neurons and Astrocytes Regulates Microglia Activation during Viral Encephalitis. <i>Cell Reports</i> , 2018, 25, 118-129.e4.	2.9	84
39	Cerebrospinal fluid JC virus antibody index for diagnosis of natalizumab-associated progressive multifocal leukoencephalopathy. <i>Annals of Neurology</i> , 2014, 76, 792-801.	2.8	82
40	Cerebrospinal fluid findings in COVID-19: a multicenter study of 150 lumbar punctures in 127 patients. <i>Journal of Neuroinflammation</i> , 2022, 19, 19.	3.1	82
41	Pivotal role of choline metabolites in remyelination. <i>Brain</i> , 2015, 138, 398-413.	3.7	80
42	Spatial and Temporal Profiles of Growth Factor Expression during CNS Demyelination Reveal the Dynamics of Repair Priming. <i>PLoS ONE</i> , 2011, 6, e22623.	1.1	80
43	Apoptosis of Myelin-Reactive T Cells Induced by Reactive Oxygen and Nitrogen Intermediates in Vitro. <i>Cellular Immunology</i> , 1997, 178, 1-8.	1.4	79
44	Natalizumab exerts a suppressive effect on surrogates of B cell function in blood and CSF. <i>Multiple Sclerosis Journal</i> , 2015, 21, 1036-1044.	1.4	78
45	Side Effects of High-Dose Intravenous Immunoglobulins. <i>Clinical Neuropharmacology</i> , 1997, 20, 385-393.	0.2	77
46	A β -Lactam Antibiotic Dampens Excitotoxic Inflammatory CNS Damage in a Mouse Model of Multiple Sclerosis. <i>PLoS ONE</i> , 2008, 3, e3149.	1.1	76
47	Mechanisms of High-Dose Intravenous Immunoglobulins in Demyelinating Diseases. <i>Archives of Neurology</i> , 1999, 56, 661.	4.9	71
48	Effects of Fumaric Acids on Cuprizone Induced Central Nervous System De- and Remyelination in the Mouse. <i>PLoS ONE</i> , 2010, 5, e11769.	1.1	71
49	Common and uncommon neurological manifestations of neuroborreliosis leading to hospitalization. <i>BMC Infectious Diseases</i> , 2017, 17, 90.	1.3	71
50	Plasma Exchange Therapy in Steroid-Unresponsive Relapses in Patients with Multiple Sclerosis. <i>Blood Purification</i> , 2009, 28, 108-115.	0.9	69
51	Clinical approach to optic neuritis: pitfalls, red flags and differential diagnosis. <i>Therapeutic Advances in Neurological Disorders</i> , 2011, 4, 123-134.	1.5	69
52	Clinical implications of serum neurofilament in newly diagnosed MS patients: A longitudinal multicentre cohort study. <i>EBioMedicine</i> , 2020, 56, 102807.	2.7	67
53	Complete Epstein-Barr virus seropositivity in a large cohort of patients with early multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020, 91, 681-686.	0.9	66
54	Effector molecules released by Th1 but not Th17 cells drive an M1 response in microglia. <i>Brain, Behavior, and Immunity</i> , 2014, 37, 248-259.	2.0	65

#	ARTICLE	IF	CITATIONS
55	Upon Intranasal Vesicular Stomatitis Virus Infection, Astrocytes in the Olfactory Bulb Are Important Interferon Beta Producers That Protect from Lethal Encephalitis. <i>Journal of Virology</i> , 2015, 89, 2731-2738.	1.5	64
56	Neuro-Sjögren: Peripheral Neuropathy With Limb Weakness in Sjögren's Syndrome. <i>Frontiers in Immunology</i> , 2019, 10, 1600.	2.2	64
57	Fluorodeoxyglucose positron emission tomography (FDG-PET) is useful in the diagnosis of neurosarcooidosis. <i>Journal of the Neurological Sciences</i> , 2009, 287, 257-259.	0.3	61
58	Synaptophysin Is a Reliable Marker for Axonal Damage. <i>Journal of Neuropathology and Experimental Neurology</i> , 2017, 76, 109-125.	0.9	61
59	Lipid nanoparticle-mediated siRNA delivery for safe targeting of human CML in vivo. <i>Annals of Hematology</i> , 2019, 98, 1905-1918.	0.8	61
60	Therapeutic Potential of Mesenchymal Stromal Cells and MSC Conditioned Medium in Amyotrophic Lateral Sclerosis (ALS) - In Vitro Evidence from Primary Motor Neuron Cultures, NSC-34 Cells, Astrocytes and Microglia. <i>PLoS ONE</i> , 2013, 8, e72926.	1.1	60
61	Influence of female sex and fertile age on neuromyelitis optica spectrum disorders. <i>Multiple Sclerosis Journal</i> , 2017, 23, 1092-1103.	1.4	60
62	Antibody-based therapy in Alzheimer's disease. <i>Expert Opinion on Biological Therapy</i> , 2011, 11, 343-357.	1.4	56
63	Modulation of rat oligodendrocyte precursor cells by the chemokine CXCL12. <i>NeuroReport</i> , 2006, 17, 1187-1190.	0.6	55
64	Immunophenotyping of Cerebrospinal Fluid Cells in Multiple Sclerosis. <i>JAMA Neurology</i> , 2014, 71, 905.	4.5	54
65	Treatment choices and neuropsychological symptoms of a large cohort of early MS. <i>Neurology: Neuroimmunology and Neuroinflammation</i> , 2018, 5, e446.	3.1	54
66	Glatiramer Acetate Modulates TNF- α and IL-10 Secretion in Microglia and Promotes Their Phagocytic Activity. <i>Journal of NeuroImmune Pharmacology</i> , 2011, 6, 381-388.	2.1	53
67	Revised McDonald criteria: The persisting importance of cerebrospinal fluid analysis. <i>Annals of Neurology</i> , 2011, 70, 520-520.	2.8	53
68	Experience in Multiple Sclerosis Patients with COVID-19 and Disease-Modifying Therapies: A Review of 873 Published Cases. <i>Journal of Clinical Medicine</i> , 2020, 9, 4067.	1.0	53
69	Beneficial Effects of Minocycline on Cuprizone Induced Cortical Demyelination. <i>Neurochemical Research</i> , 2010, 35, 1422-1433.	1.6	52
70	Impact of the McDonald Criteria 2017 on Early Diagnosis of Relapsing-Remitting Multiple Sclerosis. <i>Frontiers in Neurology</i> , 2019, 10, 188.	1.1	52
71	Basic principles of intravenous immunoglobulin (IVIg) treatment. <i>Journal of Neurology</i> , 2006, 253, v18-v24.	1.8	48
72	Association of Intrathecal Immunoglobulin G Synthesis With Disability Worsening in Multiple Sclerosis. <i>JAMA Neurology</i> , 2019, 76, 841.	4.5	48

#	ARTICLE	IF	CITATIONS
73	Oligodendroglia are protected from antibody-mediated complement injury by normal immunoglobulins (â€œIVIgâ€œ). <i>Journal of Neuroimmunology</i> , 2000, 103, 195-201.	1.1	47
74	Polyclonal immunoglobulins (IVIg) modulate nitric oxide production and microglial functions in vitro via Fc receptors. <i>Journal of Neuroimmunology</i> , 2001, 112, 63-71.	1.1	46
75	Importance of cerebrospinal fluid analysis in the era of McDonald 2010 criteria: a Germanâ€œAustrian retrospective multicenter study in patients with a clinically isolated syndrome. <i>Journal of Neurology</i> , 2016, 263, 2499-2504.	1.8	46
76	Effects of interferon-Î² on co-signaling molecules: upregulation of CD40, CD86 and PD-L2 on monocytes in relation to clinical response to interferon-Î² treatment in patients with multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2008, 14, 166-176.	1.4	45
77	Update on treatment options for Lambert–Eaton myasthenic syndrome: focus on use of amifampridine. <i>Neuropsychiatric Disease and Treatment</i> , 2011, 7, 341.	1.0	45
78	Neuroprotection and neuroregeneration in multiple sclerosis. <i>Journal of Neurology</i> , 2008, 255, 77-81.	1.8	43
79	Effects of Murine and Human Bone Marrow-Derived Mesenchymal Stem Cells on Cuprizone Induced Demyelination. <i>PLoS ONE</i> , 2013, 8, e69795.	1.1	43
80	Varicella zoster virus infections in neurological patients: a clinical study. <i>BMC Infectious Diseases</i> , 2018, 18, 238.	1.3	41
81	Matrix Metalloproteinases and Their Tissue Inhibitors in Cuprizone-Induced Demyelination and Remyelination of Brain White and Gray Matter. <i>Journal of Neuropathology and Experimental Neurology</i> , 2011, 70, 758-769.	0.9	40
82	Deregulation of microRNA-181c in cerebrospinal fluid of patients with clinically isolated syndrome is associated with early conversion to relapsing–remitting multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2016, 22, 1202-1214.	1.4	40
83	Decreased plasma phospholipid concentrations and increased acid sphingomyelinase activity are accurate biomarkers for community-acquired pneumonia. <i>Journal of Translational Medicine</i> , 2019, 17, 365.	1.8	38
84	Leptomeningeal Metastasis: The Role of Cerebrospinal Fluid Diagnostics. <i>Frontiers in Neurology</i> , 2019, 10, 839.	1.1	38
85	Active Case Finding of Current Bornavirus Infections in Human Encephalitis Cases of Unknown Etiology, Germany, 2018–2020. <i>Emerging Infectious Diseases</i> , 2021, 27, 1371-1379.	2.0	38
86	Sunlight exposure exerts immunomodulatory effects to reduce multiple sclerosis severity. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	38
87	The chemokine receptor CXCR2 is differentially regulated on glial cells <i>in vivo</i> but is not required for successful remyelination after cuprizone–induced demyelination. <i>Glia</i> , 2008, 56, 1104-1113.	2.5	37
88	Polysialic acid on SynCAM 1 in NG2 cells and on neuropilin–2 in microglia is confined to intracellular pools that are rapidly depleted upon stimulation. <i>Glia</i> , 2015, 63, 1240-1255.	2.5	37
89	Kynurenine Is a Cerebrospinal Fluid Biomarker for Bacterial and Viral Central Nervous System Infections. <i>Journal of Infectious Diseases</i> , 2019, 220, 127-138.	1.9	37
90	Glatiramer Acetate Increases Phagocytic Activity of Human Monocytes In Vitro and in Multiple Sclerosis Patients. <i>PLoS ONE</i> , 2012, 7, e51867.	1.1	36

#	ARTICLE	IF	CITATIONS
91	Pathogenic and physiological autoantibodies in the central nervous system. <i>Immunological Reviews</i> , 2012, 248, 68-86.	2.8	36
92	In vitro evaluation of physiologically relevant concentrations of teriflunomide on activation and proliferation of primary rodent microglia. <i>Journal of Neuroinflammation</i> , 2016, 13, 250.	3.1	36
93	McDonald Criteria 2010 and 2005 Compared: Persistence of High Oligoclonal Band Prevalence Despite Almost Doubled Diagnostic Sensitivity. <i>International Journal of Molecular Sciences</i> , 2016, 17, 1592.	1.8	34
94	The Persisting Significance of Oligoclonal Bands in the Dawning Era of Kappa Free Light Chains for the Diagnosis of Multiple Sclerosis. <i>International Journal of Molecular Sciences</i> , 2018, 19, 3796.	1.8	34
95	Remyelination after cuprizone induced demyelination is accelerated in mice deficient in the polysialic acid synthesizing enzyme St8siaIV. <i>Neuroscience</i> , 2010, 171, 235-244.	1.1	33
96	Lack of interferon-beta leads to accelerated remyelination in a toxic model of central nervous system demyelination. <i>Acta Neuropathologica</i> , 2007, 114, 587-596.	3.9	32
97	Immunoabsorption Therapy for Steroid-Unresponsive Relapses in Patients with Multiple Sclerosis. <i>Blood Purification</i> , 2012, 33, 1-6.	0.9	32
98	Polyclonal immunoglobulins for intravenous use do not influence the behaviour of cultured oligodendrocytes. <i>Journal of Neuroimmunology</i> , 1999, 96, 228-233.	1.1	31
99	Effects of interferon-beta on oligodendroglial cells. <i>Journal of Neuroimmunology</i> , 2006, 177, 173-180.	1.1	30
100	Cuprizone inhibits demyelinating leukomyelitis by reducing immune responses without virus exacerbation in an infectious model of multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2012, 244, 84-93.	1.1	29
101	Importance of Follow-Up Cerebrospinal Fluid Analysis in Cryptococcal Meningoencephalitis. <i>Disease Markers</i> , 2014, 2014, 1-10.	0.6	29
102	Management of patients with malignancies and secondary immunodeficiencies treated with immunoglobulins in clinical practice: Long-term data of the SIGNS study. <i>European Journal of Haematology</i> , 2017, 99, 169-177.	1.1	29
103	Longitudinal prevalence and determinants of pain in multiple sclerosis: results from the German National Multiple Sclerosis Cohort study. <i>Pain</i> , 2020, 161, 787-796.	2.0	29
104	2-Chlorodeoxyadenosine (cladribine) induces apoptosis in human monocyte-derived dendritic cells. <i>Clinical and Experimental Immunology</i> , 2013, 173, 288-297.	1.1	28
105	Subcutaneous immunoglobulin treatment of inclusion-body myositis stabilizes dysphagia. <i>Muscle and Nerve</i> , 2013, 48, 838-839.	1.0	28
106	IFN- β Producing Th1 Cells Induce Different Transcriptional Profiles in Microglia and Astrocytes. <i>Frontiers in Cellular Neuroscience</i> , 2018, 12, 352.	1.8	28
107	Case Report: Daratumumab in a Patient With Severe Refractory Anti-NMDA Receptor Encephalitis. <i>Frontiers in Neurology</i> , 2020, 11, 602102.	1.1	28
108	Fumarates for the treatment of multiple sclerosis: potential mechanisms of action and clinical studies. <i>Expert Review of Neurotherapeutics</i> , 2008, 8, 1683-1690.	1.4	27

#	ARTICLE	IF	CITATIONS
109	Cerebrospinal Fluid Findings in Neurological Diseases Associated with Sjögren's Syndrome. <i>European Neurology</i> , 2017, 77, 91-102.	0.6	27
110	Effects of fumaric acid esters on blood-brain barrier tight junction proteins. <i>Neuroscience Letters</i> , 2013, 555, 165-170.	1.0	26
111	Ovarectomy despite Negative Imaging in Anti-NMDA Receptor Encephalitis: Effective Even Late. <i>Case Reports in Neurological Medicine</i> , 2013, 2013, 1-3.	0.3	26
112	Polysialylation at Early Stages of Oligodendrocyte Differentiation Promotes Myelin Repair. <i>Journal of Neuroscience</i> , 2017, 37, 8131-8141.	1.7	26
113	Alemtuzumab therapy changes immunoglobulin levels in peripheral blood and CSF. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2020, 7, e654.	3.1	26
114	Delayed Demyelination and Impaired Remyelination in Aged Mice in the Cuprizone Model. <i>Cells</i> , 2020, 9, 945.	1.8	26
115	Lipopolysaccharide delays demyelination and promotes oligodendrocyte precursor proliferation in the central nervous system. <i>Brain, Behavior, and Immunity</i> , 2011, 25, 1592-1606.	2.0	25
116	Effects of 2-Chlorodeoxyadenosine (Cladribine) on Primary Rat Microglia. <i>Journal of NeuroImmune Pharmacology</i> , 2012, 7, 939-950.	2.1	25
117	Dimethyl fumarate (BG-12) for the treatment of multiple sclerosis. <i>Expert Review of Clinical Pharmacology</i> , 2013, 6, 355-362.	1.3	25
118	Mesenchymal stem cells do not exert direct beneficial effects on CNS remyelination in the absence of the peripheral immune system. <i>Brain, Behavior, and Immunity</i> , 2015, 50, 155-165.	2.0	25
119	The quality of cortical network function recovery depends on localization and degree of axonal demyelination. <i>Brain, Behavior, and Immunity</i> , 2017, 59, 103-117.	2.0	25
120	The Impact of Immunomodulatory Treatment on Kappa Free Light Chains as Biomarker in Neuroinflammation. <i>Cells</i> , 2020, 9, 842.	1.8	25
121	Intrathecal synthesis of anti-Hu antibodies distinguishes patients with paraneoplastic peripheral neuropathy and encephalitis. <i>BMC Neurology</i> , 2016, 16, 136.	0.8	24
122	The Influence of Blood Contamination on Cerebrospinal Fluid Diagnostics. <i>Frontiers in Neurology</i> , 2019, 10, 584.	1.1	24
123	Reiber's Diagram for Kappa Free Light Chains: The New Standard for Assessing Intrathecal Synthesis?. <i>Diagnostics</i> , 2019, 9, 194.	1.3	24
124	Can we predict cognitive decline after initial diagnosis of multiple sclerosis? Results from the German National early MS cohort (KKNMS). <i>Journal of Neurology</i> , 2019, 266, 386-397.	1.8	24
125	Cuprizone-induced demyelination triggers a CD8 ⁺ -pronounced T cell recruitment. <i>Glia</i> , 2021, 69, 925-942.	2.5	24
126	Quantification of Microglial Phagocytosis by a Flow Cytometer-Based Assay. <i>Methods in Molecular Biology</i> , 2013, 1041, 121-127.	0.4	23

#	ARTICLE	IF	CITATIONS
127	Nitric oxide/cyclic GMP signaling regulates motility of a microglial cell line and primary microglia in vitro. <i>Brain Research</i> , 2014, 1564, 9-21.	1.1	23
128	Effect of FTY720-phosphate on the expression of inflammation-associated molecules in astrocytes in vitro. <i>Molecular Medicine Reports</i> , 2015, 12, 6171-6177.	1.1	23
129	Clinically Isolated Syndrome According to McDonald 2010: Intrathecal IgG Synthesis Still Predictive for Conversion to Multiple Sclerosis. <i>International Journal of Molecular Sciences</i> , 2017, 18, 2061.	1.8	23
130	Acute progressive neuropathyâ€“myositisâ€“myasthenia-like syndrome associated with immune-checkpoint inhibitor therapy in patients with metastatic melanoma. <i>Melanoma Research</i> , 2019, 29, 435-440.	0.6	23
131	CD19 as a molecular target in CNS autoimmunity. <i>Acta Neuropathologica</i> , 2014, 128, 177-190.	3.9	22
132	Mass-spectrometric profiling of cerebrospinal fluid reveals metabolite biomarkers for CNS involvement in varicella zoster virus reactivation. <i>Journal of Neuroinflammation</i> , 2018, 15, 20.	3.1	22
133	Fumaric Acids Directly Influence Gene Expression of Neuroprotective Factors in Rodent Microglia. <i>International Journal of Molecular Sciences</i> , 2019, 20, 325.	1.8	22
134	The 5-year Tysabri global observational program in safety (TYGRIS) study confirms the long-term safety profile of natalizumab treatment in multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 39, 101863.	0.9	22
135	The Effect of Stereotactic Injections on Demyelination and Remyelination: a Study in the Cuprizone Model. <i>Journal of Molecular Neuroscience</i> , 2017, 61, 479-488.	1.1	21
136	Cerebrospinal fluid features in adults with enteroviral nervous system infection. <i>International Journal of Infectious Diseases</i> , 2018, 68, 94-101.	1.5	21
137	Oligodendrocyte precursor cells express a functional chemokine receptor CCR3: Implications for myelination. <i>Journal of Neuroimmunology</i> , 2006, 178, 17-23.	1.1	20
138	Implications of COVID-19 Outbreak on Immune Therapies in Multiple Sclerosis Patientsâ€“Lessons Learned From SARS and MERS. <i>Frontiers in Immunology</i> , 2020, 11, 1059.	2.2	20
139	Mild COVID-19 symptoms despite treatment with teriflunomide and high-dose methylprednisolone due to multiple sclerosis relapse. <i>Journal of Neurology</i> , 2020, 267, 2803-2805.	1.8	20
140	Polyclonal IgM influence oligodendrocyte precursor cells in mixed glial cell cultures: implications for remyelination. <i>Journal of Neuroimmunology</i> , 2003, 138, 25-30.	1.1	19
141	Varicella zoster-associated retinal and central nervous system vasculitis in a patient with multiple sclerosis treated with natalizumab. <i>Journal of Neuroinflammation</i> , 2014, 11, 19.	3.1	19
142	Gain-of-function STAT1 mutations are associated with intracranial aneurysms. <i>Clinical Immunology</i> , 2017, 178, 79-85.	1.4	19
143	Allogeneic BK Virus-Specific T-Cell Treatment in 2 Patients With Progressive Multifocal Leukoencephalopathy. <i>Neurology: Neuroimmunology and Neuroinflammation</i> , 2021, 8, e1020.	3.1	19
144	Evidence of Oligoclonal Bands Does Not Exclude Non-Inflammatory Neurological Diseases. <i>Diagnostics</i> , 2021, 11, 37.	1.3	19

#	ARTICLE	IF	CITATIONS
145	Long-term impact of neonatal inflammation on demyelination and remyelination in the central nervous system. <i>Glia</i> , 2014, 62, 1659-1670.	2.5	18
146	Heterogeneity of clinical features and corresponding antibodies in seven patients with anti-NMDA receptor encephalitis. <i>Experimental and Therapeutic Medicine</i> , 2015, 10, 1283-1292.	0.8	18
147	Cytokine regulation by modulation of the NMDA receptor on astrocytes. <i>Neuroscience Letters</i> , 2016, 629, 227-233.	1.0	18
148	Intrathecal Antibody Production Against Epstein-Barr, Herpes Simplex, and Other Neurotropic Viruses in Autoimmune Encephalitis. <i>Neurology: Neuroimmunology and Neuroinflammation</i> , 2021, 8, .	3.1	18
149	Comparison of Intravenous Immunoglobulin Preparations on Microglial Function In Vitro: More Potent Immunomodulatory Capacity of an IgM/IgA-Enriched Preparation. <i>Clinical Neuropharmacology</i> , 2002, 25, 254-259.	0.2	17
150	Remyelinating and neuroprotective treatments in multiple sclerosis. <i>Expert Opinion on Investigational Drugs</i> , 2004, 13, 331-347.	1.9	17
151	Varicella Zoster Virus Meningitis in a Young Immunocompetent Adult without Rash: A Misleading Clinical Presentation. <i>Case Reports in Neurological Medicine</i> , 2014, 2014, 1-4.	0.3	17
152	Applying the 2017 McDonald diagnostic criteria for multiple sclerosis. <i>Lancet Neurology</i> , The, 2018, 17, 498.	4.9	17
153	Mesenchymal Stem Cells Form 3D Clusters Following Intraventricular Transplantation. <i>Journal of Molecular Neuroscience</i> , 2018, 65, 60-73.	1.1	17
154	Immunity in Gilles de la Tourette-Syndrome: Results From a Cerebrospinal Fluid Study. <i>Frontiers in Neurology</i> , 2019, 10, 732.	1.1	17
155	Subcortical Volumes as Early Predictors of Fatigue in Multiple Sclerosis. <i>Annals of Neurology</i> , 2022, 91, 192-202.	2.8	17
156	Presentation and Prognosis of Bilateral Infarcts in the Territory of the Superior Cerebellar Artery. <i>Cerebrovascular Diseases</i> , 1999, 9, 328-333.	0.8	16
157	Limited role of regulatory T cells during acute Theiler virus-induced encephalitis in resistant C57BL/6 mice. <i>Journal of Neuroinflammation</i> , 2014, 11, 180.	3.1	16
158	Investigation of Oligoclonal IgG Bands in Tear Fluid of Multiple Sclerosis Patients. <i>Frontiers in Immunology</i> , 2019, 10, 1110.	2.2	16
159	HSV-1 triggers paracrine fibroblast growth factor response from cortical brain cells via immediate-early protein ICPO. <i>Journal of Neuroinflammation</i> , 2019, 16, 248.	3.1	16
160	Epidemiology, characteristics and treatment of patients with relapsing remitting multiple sclerosis and incidence of high disease activity: Real world evidence based on German claims data. <i>PLoS ONE</i> , 2020, 15, e0231846.	1.1	16
161	Quantification of polyreactive immunoglobulin G facilitates the diagnosis of autoimmune hepatitis. <i>Hepatology</i> , 2022, 75, 13-27.	3.6	16
162	Safety and efficacy of erythropoietin for the treatment of patients with optic neuritis (TONE): a randomised, double-blind, multicentre, placebo-controlled study. <i>Lancet Neurology</i> , The, 2021, 20, 991-1000.	4.9	16

#	ARTICLE	IF	CITATIONS
163	The fumaric acid ester BG-12: a new option in MS therapy. <i>Expert Review of Neurotherapeutics</i> , 2013, 13, 951-958.	1.4	15
164	A pivotal role of nonmuscle myosin II during microglial activation. <i>Experimental Neurology</i> , 2014, 261, 666-676.	2.0	15
165	Successful Replication of GWAS Hits for Multiple Sclerosis in 10,000 Germans Using the Exome Array. <i>Genetic Epidemiology</i> , 2015, 39, 601-608.	0.6	15
166	Design of TRUST, a non-interventional, multicenter, 3-year prospective study investigating an integrated patient management approach in patients with relapsing-remitting multiple sclerosis treated with natalizumab. <i>BMC Neurology</i> , 2016, 16, 98.	0.8	15
167	Impairment of frequency-specific responses associated with altered electrical activity patterns in auditory thalamus following focal and general demyelination. <i>Experimental Neurology</i> , 2018, 309, 54-66.	2.0	15
168	Placebo effect in chronic inflammatory demyelinating polyneuropathy: The <sc>PATH</sc> study and a systematic review. <i>Journal of the Peripheral Nervous System</i> , 2020, 25, 230-237.	1.4	15
169	CIDP associated with Sjögren's syndrome. <i>Journal of Neurology</i> , 2021, 268, 2908-2912.	1.8	15
170	Oxides and apoptosis in inflammatory myopathies. <i>Microscopy Research and Technique</i> , 2001, 55, 249-258.	1.2	14
171	Acute hemorrhagic leukoencephalitis (Weston-Hurst syndrome) in a patient with relapse-remitting multiple sclerosis. <i>Journal of Neuroinflammation</i> , 2015, 12, 175.	3.1	14
172	Treatment of patients with multifocal motor neuropathy with immunoglobulins in clinical practice: the SIGNS registry. <i>Therapeutic Advances in Neurological Disorders</i> , 2016, 9, 165-179.	1.5	14
173	Routine Cerebrospinal Fluid Cytology Reveals Unique Inclusions in Macrophages During Treatment With Nusinersen. <i>Frontiers in Neurology</i> , 2019, 10, 735.	1.1	14
174	Identification of Cerebrospinal Fluid Metabolites as Biomarkers for Enterovirus Meningitis. <i>International Journal of Molecular Sciences</i> , 2019, 20, 337.	1.8	14
175	Cognitive impairment in patients with Neuro-Sjögren. <i>Annals of Clinical and Translational Neurology</i> , 2020, 7, 1352-1359.	1.7	14
176	Treatment of upper limb spasticity with inhibitory repetitive transcranial magnetic stimulation: A randomized placebo-controlled trial. <i>NeuroRehabilitation</i> , 2021, 49, 425-434.	0.5	14
177	Introduction and spread of variegated squirrel bornavirus 1 (VSBV-1) between exotic squirrels and spill-over infections to humans in Germany. <i>Emerging Microbes and Infections</i> , 2021, 10, 602-611.	3.0	14
178	Costs and Health-Related Quality of Life in Patients With NMO Spectrum Disorders and MOG-Antibody-Associated Disease. <i>Neurology</i> , 2022, 98, .	1.5	14
179	The antiviral drug ganciclovir does not inhibit microglial proliferation and activation. <i>Scientific Reports</i> , 2015, 5, 14935.	1.6	13
180	Fingolimod Associated Bilateral Cystoid Macular Edema—Wait and See?. <i>International Journal of Molecular Sciences</i> , 2016, 17, 2106.	1.8	13

#	ARTICLE	IF	CITATIONS
181	Immunophenotyping of cerebrospinal fluid cells by Chipcytometry. <i>Journal of Neuroinflammation</i> , 2018, 15, 160.	3.1	13
182	Therapy with cladribine is efficient and safe in patients previously treated with natalizumab. <i>Therapeutic Advances in Neurological Disorders</i> , 2019, 12, 175628641988759.	1.5	13
183	Emerging myelin repair agents in preclinical and early clinical development for the treatment of multiple sclerosis. <i>Expert Opinion on Investigational Drugs</i> , 2020, 29, 583-594.	1.9	13
184	The influence of the CRS-R score on functional outcome in patients with severe brain injury receiving early rehabilitation. <i>BMC Neurology</i> , 2021, 21, 44.	0.8	13
185	Rat oligodendroglial cell lines express a functional receptor for the chemokine CCL3 (macrophage) Tj ETQq1 1 0.784314 rgBT ₁₂ /Overlook	1.0	12
186	Severe Anti-N-Methyl-D-Aspartate Receptor Encephalitis Under Immunosuppression After Liver Transplantation. <i>Frontiers in Neurology</i> , 2019, 10, 987.	1.1	12
187	Phosphatidylcholine PC ae C44:6 in cerebrospinal fluid is a sensitive biomarker for bacterial meningitis. <i>Journal of Translational Medicine</i> , 2020, 18, 9.	1.8	12
188	Cerebrospinal Fluid Parameters in Antisense Oligonucleotide-Treated Adult 5q-Spinal Muscular Atrophy Patients. <i>Brain Sciences</i> , 2021, 11, 296.	1.1	12
189	MyD88 signaling by neurons induces chemokines that recruit protective leukocytes to the virus-infected CNS. <i>Science Immunology</i> , 2021, 6, .	5.6	12
190	The choline pathway as a strategy to promote central nervous system (CNS) remyelination. <i>Neural Regeneration Research</i> , 2015, 10, 1369.	1.6	12
191	Astroglial and oligodendroglial markers in the cuprizone animal model for de- and remyelination. <i>Histochemistry and Cell Biology</i> , 2022, 158, 15-38.	0.8	12
192	Neurodegeneration and Neuroprotection in Multiple Sclerosis. <i>Current Pharmaceutical Design</i> , 2012, 18, 4471-4474.	0.9	11
193	Investigation of Neuregulin-1 and Glial Cell-Derived Neurotrophic Factor in Rodent Astrocytes and Microglia. <i>Journal of Molecular Neuroscience</i> , 2019, 67, 484-493.	1.1	11
194	Severe Progressive Multifocal Leukoencephalopathy (PML) and Spontaneous Immune Reconstitution Inflammatory Syndrome (IRIS) in an Immunocompetent Patient. <i>Frontiers in Immunology</i> , 2019, 10, 1188.	2.2	11
195	Is APOE ϵ 4 associated with cognitive performance in early MS?. <i>Neurology: Neuroimmunology and Neuroinflammation</i> , 2020, 7, e728.	3.1	11
196	Current issues in immunomodulatory treatment of multiple sclerosis. <i>Journal of Neurology</i> , 2006, 253, i32-i36.	1.8	10
197	Nervous system involvement of connective tissue disease. <i>Current Opinion in Neurology</i> , 2012, 25, 306-315.	1.8	10
198	Gilles de la Tourette syndrome is not linked to contactin-associated protein receptor 2 antibodies. <i>Molecular Brain</i> , 2015, 8, 62.	1.3	10

#	ARTICLE	IF	CITATIONS
199	Oligodendroglial markers in the cuprizone model of CNS de- and remyelination. <i>Histology and Histopathology</i> , 2015, 30, 1455-64.	0.5	10
200	Toll-like Receptors in Viral Encephalitis. <i>Viruses</i> , 2021, 13, 2065.	1.5	10
201	The Influence of Renal Function Impairment on Kappa Free Light Chains in Cerebrospinal Fluid. <i>Journal of Central Nervous System Disease</i> , 2021, 13, 117957352110421.	0.7	10
202	Bloodâ€“cerebrospinal fluid barrier dysfunction in patients with neurological symptoms during the 2011 Northern German E. coli serotype O104:H4 outbreak. <i>Brain</i> , 2013, 136, e241-e241.	3.7	9
203	Longitudinal time-domain optic coherence study of retinal nerve fiber layer in IFNÎ²-treated and untreated multiple sclerosis patients. <i>Experimental and Therapeutic Medicine</i> , 2016, 12, 190-200.	0.8	9
204	Paraneoplastic cerebellar syndromes associated with antibodies against Purkinje cells. <i>International Journal of Neuroscience</i> , 2018, 128, 721-728.	0.8	9
205	Hearing dysfunction in patients with Neuro-SjÃ¶gren: a cross-sectional study. <i>Annals of Translational Medicine</i> , 2020, 8, 1069-1069.	0.7	9
206	Elevated Free Phosphatidylcholine Levels in Cerebrospinal Fluid Distinguish Bacterial from Viral CNS Infections. <i>Cells</i> , 2021, 10, 1115.	1.8	9
207	PD-1-inhibitor pembrolizumab for treatment of progressive multifocal leukoencephalopathy. <i>Therapeutic Advances in Neurological Disorders</i> , 2021, 14, 175628642199368.	1.5	9
208	Regulation of neuroinflammatory properties of glial cells by T cell effector molecules. <i>Neural Regeneration Research</i> , 2018, 13, 234.	1.6	9
209	Neurological management and work-up of neurotoxicity associated with CAR T cell therapy. <i>Neurological Research and Practice</i> , 2022, 4, 1.	1.0	9
210	Remyelination strategies: New advancements toward a regenerative treatment in multiple sclerosis. <i>Current Neurology and Neuroscience Reports</i> , 2006, 6, 229-235.	2.0	8
211	Specific Immune Intervention with Monoclonal Antibodies for the Treatment of Multiple Sclerosis. <i>Current Medicinal Chemistry</i> , 2010, 17, 640-650.	1.2	8
212	Treatment of Neurological Autoimmune Diseases with Immunoglobulins: First Insights from the Prospective SIGNS Registry. <i>Journal of Clinical Immunology</i> , 2013, 33, 67-71.	2.0	8
213	Effect of interferon-Î²1b on CXCR4-dependent chemotaxis in T cells from multiple sclerosis patients. <i>Clinical and Experimental Immunology</i> , 2015, 182, 162-172.	1.1	8
214	Autoantibodies binding to stathmin-4: new marker for polyneuropathy in primary SjÃ¶grenâ€™s syndrome. <i>Immunologic Research</i> , 2017, 65, 1099-1102.	1.3	8
215	Automated Analysis of Cerebrospinal Fluid Cells Using Commercially Available Blood Cell Analysis Devicesâ€“A Critical Appraisal. <i>Cells</i> , 2021, 10, 1232.	1.8	8
216	Natalizumab to fingolimodâ€“the washout whitewash. <i>Nature Reviews Neurology</i> , 2014, 10, 311-313.	4.9	7

#	ARTICLE	IF	CITATIONS
217	Astrocytes Enhance Streptococcus suis-Glial Cell Interaction in Primary Astrocyte-Microglial Cell Co-Cultures. <i>Pathogens</i> , 2016, 5, 43.	1.2	7
218	Chronic Granulomatous Disease First Diagnosed in Adulthood Presenting With Spinal Cord Infection. <i>Frontiers in Immunology</i> , 2018, 9, 1258.	2.2	7
219	Genetic determinants of the humoral immune response in MS. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2020, 7, e827.	3.1	7
220	Auditory Stimulation Modulates Resting-State Functional Connectivity in Unresponsive Wakefulness Syndrome Patients. <i>Frontiers in Neuroscience</i> , 2021, 15, 554194.	1.4	7
221	Hematopoietic stem cell transplantation: hope and hype. <i>Nature Reviews Neurology</i> , 2009, 5, 300-302.	4.9	6
222	Interferon-beta treatment normalises the inhibitory effect of serum from multiple sclerosis patients on oligodendrocyte progenitor proliferation. <i>Neuroscience Letters</i> , 2010, 485, 107-111.	1.0	6
223	Investigation of Cuprizone Inactivation by Temperature. <i>Neurotoxicity Research</i> , 2017, 31, 570-577.	1.3	6
224	Weaning of neurological early rehabilitation patients from mechanical ventilation: a retrospective observational study. <i>European Journal of Physical and Rehabilitation Medicine</i> , 2017, 53, 441-446.	1.1	6
225	Diagnosis and Differential Diagnosis of Neurological Adverse Events during Immune Checkpoint Inhibitor Therapy. <i>Journal of Oncology</i> , 2020, 2020, 1-9.	0.6	6
226	Severe allo-immune antibody-associated peripheral and central nervous system diseases after allogeneic hematopoietic stem cell transplantation. <i>Scientific Reports</i> , 2021, 11, 8527.	1.6	6
227	Rare germline variants in the E-cadherin gene CDH1 are associated with the risk of brain tumors of neuroepithelial and epithelial origin. <i>Acta Neuropathologica</i> , 2021, 142, 191-210.	3.9	6
228	Sequential MAVS and MyD88/TRIF signaling triggers anti-viral responses of tick-borne encephalitis virus-infected murine astrocytes. <i>Journal of Neuroscience Research</i> , 2021, 99, 2478-2492.	1.3	6
229	Review: New advances in the treatment of neurological diseases using high dose intravenous immunoglobulins. <i>Therapeutic Advances in Neurological Disorders</i> , 2008, 1, 115-124.	1.5	5
230	Using immunoglobulins in muscular disease treatment. <i>Expert Opinion on Biological Therapy</i> , 2008, 8, 1143-1150.	1.4	5
231	CDP-choline is not protective in the SOD1-G93A mouse model of ALS. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2013, 14, 284-290.	1.1	5
232	Fumaric Acids Do Not Directly Influence Gene Expression of Neuroprotective Factors in Highly Purified Rodent Astrocytes. <i>Brain Sciences</i> , 2019, 9, 241.	1.1	5
233	Polarized microglia do not influence oligodendrocyte lineage cells via astrocytes. <i>International Journal of Developmental Neuroscience</i> , 2019, 77, 39-47.	0.7	5
234	Cerebrospinal fluid analysis in 108 patients with progressive multifocal leukoencephalopathy. <i>Fluids and Barriers of the CNS</i> , 2020, 17, 65.	2.4	5

#	ARTICLE	IF	CITATIONS
235	Development of Registry Data to Create Interactive Doctor-Patient Platforms for Personalized Patient Care, Taking the Example of the DESTINY System. <i>Frontiers in Digital Health</i> , 2021, 3, 633427.	1.5	5
236	Nerve ultrasound findings in Sjögren's syndrome-associated neuropathy. <i>Journal of Neuroimaging</i> , 2021, 31, 1156-1165.	1.0	5
237	Contribution of QSM Imaging to the Diagnosis of the Rare Syndrome of Leukoencephalopathy with Cysts and Calcification (LCC). <i>Clinical Neuroradiology</i> , 2017, 27, 477-479.	1.0	5
238	Structural analysis of the rat T-cell receptor Tcra V4 gene family. <i>Immunogenetics</i> , 1995, 41, 125-30.	1.2	4
239	Meningeal carcinomatosis from penile squamous cell carcinoma. <i>Journal of Neuro-Oncology</i> , 2010, 98, 417-419.	1.4	4
240	3,4-Diaminopyridine (amifampridine) for the treatment of Lambert-Eaton myasthenic syndrome. <i>Expert Opinion on Orphan Drugs</i> , 2014, 2, 293-300.	0.5	4
241	Differentiation of viral and autoimmune central nervous system inflammation by kynurenine pathway. <i>Annals of Clinical and Translational Neurology</i> , 2021, 8, 2228-2234.	1.7	4
242	Regenerative Effects of CDP-Choline: A Dose-Dependent Study in the Toxic Cuprizone Model of De- and Remyelination. <i>Pharmaceuticals</i> , 2021, 14, 1156.	1.7	4
243	The Influence of the Ventricular-Lumbar Gradient on Cerebrospinal Fluid Analysis in Serial Samples. <i>Brain Sciences</i> , 2022, 12, 410.	1.1	4
244	Immunoglobulins for primary or secondary immunodeficiency or for immunomodulation in neurological autoimmune diseases: insights from the prospective SIGNS registry. <i>Zeitschrift Fur Gesundheitswissenschaften</i> , 2012, 20, 289-296.	0.8	3
245	Intraspinal cavernous bleeding during early pregnancy. <i>Journal of Neurology</i> , 2016, 263, 2127-2129.	1.8	3
246	Beneficial and detrimental impact of transplanted canine adipose-derived stem cells in a virus-induced demyelinating mouse model. <i>Veterinary Immunology and Immunopathology</i> , 2018, 202, 130-140.	0.5	3
247	Tau-protein concentrations are not elevated in cerebrospinal fluid of patients with progressive multifocal leukoencephalopathy. <i>Fluids and Barriers of the CNS</i> , 2019, 16, 28.	2.4	3
248	FoxP3 deficiency causes no inflammation or neurodegeneration in the murine brain. <i>Journal of Neuroimmunology</i> , 2020, 342, 577216.	1.1	3
249	Oral pulsed therapy of relapsing multiple sclerosis with cladribine tablets – expert opinion on issues in clinical practice. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 54, 103075.	0.9	3
250	Remission of a CNS inflammatory disease accompanied by newly developed ANA and arthropathy during treatment with IFN-*. <i>Journal of Neurology</i> , 2002, 249, 1121-1122.	1.8	2
251	Defining the New End Point for Multiple Sclerosis Treatment. <i>JAMA Neurology</i> , 2014, 71, 1056.	4.5	2
252	CSF Levels of Angiopoietin-2 Do Not Differ between Patients with CSF Fluid Leakage Syndrome and Controls. <i>Disease Markers</i> , 2015, 2015, 1-9.	0.6	2

#	ARTICLE	IF	CITATIONS
253	Severe CNS inflammation after discontinuation of natalizumab and start of daclizumab successfully treated with alemtuzumab. Multiple Sclerosis and Related Disorders, 2018, 22, 87-89.	0.9	2
254	Management of MS-relapse during alemtuzumab therapy: Is it really B-cell-mediated?. Multiple Sclerosis and Related Disorders, 2018, 19, 6-7.	0.9	2
255	Targeted metabolomic profiling of cerebrospinal fluid from patients with progressive multifocal leukoencephalopathy. PLoS ONE, 2020, 15, e0242321.	1.1	2
256	Mesenchymal stem cells require the peripheral immune system for immunomodulating effects in animal models of multiple sclerosis. Neural Regeneration Research, 2016, 11, 90.	1.6	2
257	Sequence and diversity of rat T-cell receptor Tcra V8 gene segments. Immunogenetics, 1995, 42, 304-5.	1.2	1
258	B-cell lymphoma infiltration of cerebrospinal fluid with minimal symptoms and benign course. Journal of Clinical Neuroscience, 2011, 18, 978-980.	0.8	1
259	Remyelination in Multiple Sclerosis. , 2011, , 193-223.		1
260	Reply: Beneficial effects of exogenous CDP-choline (citicoline) in EAE. Brain, 2015, 138, e389-e389.	3.7	1
261	Standardized nutritional supply versus individual nutritional assessment: Impact on weight changes, complications and functional outcome from neurological early rehabilitation. Clinical Nutrition, 2020, 39, 1225-1233.	2.3	1
262	Checkpoint inhibitor-induced autoimmune central nervous system disorder in patients with metastatic melanoma and Hodgkin's lymphoma. Clinical and Experimental Neuroimmunology, 2021, 12, 127-134.	0.5	1
263	Switch from intravenous to subcutaneous immunoglobulin IgPro20 in CIDP patients: a prospective observational study under real-world conditions. Therapeutic Advances in Neurological Disorders, 2021, 14, 175628642110091.	1.5	1
264	Remyelinating and neuroprotective treatments in multiple sclerosis. Expert Opinion on Investigational Drugs, 2004, 13, 331-347.	1.9	1
265	Guillain-Barré-Syndrom (akute entzündliche demyelinisierende Polyradikuloneuritis). Intensivmedizin Und Notfallmedizin, 2003, 40, 100-110.	0.2	0
266	Rat oligodendroglial cell lines express a functional receptor for the chemokine CCL3 (macrophage) Tj ETQq0 0 0 rgBT/Overlock 10 Tf 50	1.0	0
267	Does natalizumab have a role in the treatment of relapsing multiple sclerosis?. Nature Clinical Practice Neurology, 2006, 2, 476-477.	2.7	0
268	Intravenous versus subcutaneous immunoglobulin - Authors' reply. Lancet Neurology, The, 2018, 17, 393-394.	4.9	0
269	Management of secondary immunodeficiencies with immunoglobulins (IG) under clinical practice conditions.. Journal of Clinical Oncology, 2014, 32, e17596-e17596.	0.8	0
270	Therapie der multiplen Sklerose: Medikamentöse Ansätze zur Remyelinisierung in Präfung. , 0, , .		0